Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study: Results from the Targeted Agent and Profiling Utilization Registry Study

Apar K. Ganti, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Elie G. Dib, Herbert L. Duvivier, Eugene R. Ahn, Deepti Behl, Hossein Borghaei, Ani S. Balmanoukian, Anu Gaba, Rui Li, Kwabena Osei-Boateng, Ramya Thota, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study: Results from the Targeted Agent and Profiling Utilization Registry Study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science